Navamedic ASA: Kathrine Gamborg Andreassen appointed CEO

12/21/2018 8:00:00 AM

Oslo, 21 December 2018 – Navamedic ASA (Navamedic, OSE: NAVA) today announces that the Board of Directors has appointed Kathrine Gamborg Andreassen as Chief Executive Officer. Ms. Gamborg Andreassen will assume her position effective January 1, 2019.

“I am pleased to announce Kathrine Gamborg Andreassen as the new CEO of Navamedic. Kathrine is a seasoned and experienced executive with an impressive track record in the pharma and healthcare field. Adding in her experience as the company’s former Chair of the Board, we are confident that Kathrine will utilise Navamedic's stong platform to bring new growth and value creation to the company,” says Terje Bakken, Chairman of the Board of Directors.

Kathrine Gamborg Andreassen served as Chair of the Board of Navamedic from June until December 2018. Gamborg Andreassen was the CEO of Weifa ASA until the company was acquired by Karo Pharma AB in November 2017, and also served as VP Consumer Health at Weifa. Gamborg Andreassen is the co-owner and Chair of the Board at Novicus Pharma AS. She holds a Msc in Business Strategy & Marketing from the University of Wisconsin at Madison and a BBA from Handelsakademiet/Oslo Business School.

Kathrine Gamborg Andreassen will assume her position as CEO of Navamedic effective January 1, 2019.

For further information, please contact:

Toril Ås, Chief Financial Officer at Navamedic

toril.as@navamedic.com, +47 671 12 540

Navamedic ASA is a Norwegian company within pharmaceuticals and medical technology, delivering products to patients, hospitals and pharmacies in the Nordic and selected European markets. Navamedic's business unit for pharmaceutical and healthcare products is a distributor of products supplied by a number of pharmaceutical manufacturers. Navamedic’s business within medical technology has developed and is currently introducing Sippi®, a new system for digital urine measurement. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.